---
title: "12 Health Care Stocks Moving In Friday's Intraday Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282373826.md"
description: "In Friday's trading session, Cue Biopharma saw a significant gain of 69.9%, reaching $0.5, while Plus Therapeutics and Tempest Therapeutics rose by 32.14% and 30.37%, respectively. Other notable gainers included Zentalis Pharmaceuticals and Treace Medical Concepts. Conversely, CDT Equity experienced the largest decline at 23.8%, followed by Replimune Group and Harvard Bioscience, which fell by 19.46% and 16.39%. Overall, the health care sector showed mixed performance with substantial movements in stock prices."
datetime: "2026-04-10T17:05:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282373826.md)
  - [en](https://longbridge.com/en/news/282373826.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282373826.md)
---

# 12 Health Care Stocks Moving In Friday's Intraday Session

### Gainers

-   **Cue Biopharma** (NASDAQ:CUE) shares increased by 69.9% to $0.5 during Friday's regular session. The company's market cap stands at $28.6 million.
-   **Plus Therapeutics** (NASDAQ:PSTV) shares moved upwards by 32.14% to $5.18. The company's market cap stands at $26.8 million.
-   **Tempest Therapeutics** (NASDAQ:TPST) shares rose 30.37% to $2.06. The company's market cap stands at $22.6 million.
-   **Zentalis Pharmaceuticals** (NASDAQ:ZNTL) stock rose 29.61% to $5.73. The market value of their outstanding shares is at $313.5 million.
-   **Treace Medical Concepts** (NASDAQ:TMCI) shares moved upwards by 20.58% to $1.84. The market value of their outstanding shares is at $97.4 million.
-   **Organon** (NYSE:OGN) stock moved upwards by 20.47% to $8.32. The market value of their outstanding shares is at $1.7 billion.

### Losers

-   **CDT Equity** (NASDAQ:CDT) shares declined by 23.8% to $4.49 during Friday's regular session. The market value of their outstanding shares is at $27.8 million.
-   **Replimune Group** (NASDAQ:REPL) stock declined by 19.46% to $4.76. The market value of their outstanding shares is at $463.6 million.
-   **Harvard Bioscience** (NASDAQ:HBIO) stock fell 16.39% to $4.49. The company's market cap stands at $24.0 million.
-   **Insight Molecular** (NASDAQ:IMDX) stock declined by 16.2% to $2.67. The company's market cap stands at $102.2 million.
-   **Profusa** (NASDAQ:PFSA) shares decreased by 16.09% to $0.88. The company's market cap stands at $1.4 million.
-   **Virax Biolabs Group** (NASDAQ:VRAX) shares decreased by 15.66% to $0.11. The market value of their outstanding shares is at $1.0 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)
- [TPST.US](https://longbridge.com/en/quote/TPST.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [CUE.US](https://longbridge.com/en/quote/CUE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [HBIO.US](https://longbridge.com/en/quote/HBIO.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [TMCI.US](https://longbridge.com/en/quote/TMCI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Resona Asset Management Co. Ltd. Cuts Position in Danaher Corporation $DHR](https://longbridge.com/en/news/286897088.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Cue Biopharma Q1 net loss narrows on lower R&D costs](https://longbridge.com/en/news/286463248.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)